Skip to main content

Table 5 Diagnosis, treatments and outcomes according to severity of hyponatraemia

From: Prognosis of patients with severe hyponatraemia is related not only to hyponatraemia but also to comorbidities and to medical management: results of an observational retrospective study

 

All patients

(n = 147)

Group A

(n = 20)

Group B

(n = 41)

Group C

(n = 86)

P a

Diagnosis

 Unknown (%)

69 (46.9)

6 (30.0)

16 (39.0)

47 (54.7)

.07

 Potomania (%)

8 (5.4)

3 (15.0)

3 (7.3)

2 (2.3)

.04

 Heart failure (%)

13 (8.8)

1 (5.0)

2 (4.9)

10 (11.6)

.37

 Cirrhosis (%)

4 (2.7)

0 (0)

1 (2.4)

3 (3.5)

.68

 Diuretics (%)

6 (4.1)

1 (5.0)

1 (2.4)

4 (4.7)

.82

 Hypotonic fluids (%)

3 (2.0)

0 (0)

1 (2.4)

2 (2.3)

1.0

 Dehydration (%)

22 (15.0)

4 (20.0)

7 (17.1)

11 (12.8)

.61

 CSWS (%)

2 (1.4)

0 (0)

1 (2.4)

1 (1.2)

.66

 SIADH (%)

28 (19.1)

6 (30.0)

12 (29.3)

10 (11.6)

.03

 Hypothyroidism (%)

3 (2.0)

2 (10.0)

1 (2.4)

0 (0)

.02

 Adrenal insufficiency (%)

4 (2.7)

1 (5.0)

0 (0)

3 (3.5)

.42

Treatment (%)

127 (86.4)

20 (100)

37 (90.2)

70 (81.4)

.06

- Fluid restriction (%)

- Cause withdrawal (%)

- Isotonic saline (%)

- Hypertonic saline (%)

- Furosemide (%)

- Demeclocycline (%)

93 (63.3)

31 (21.1)

67 (45.6)

16 (10.9)

19 (12.9)

10 (6.8)

17 (85.0)

8 (40.0)

8 (40.0)

9 (45.0)

2 (10.0)

4 (20.0)

28 (68.3)

9 (22.0)

22 (53.7)

2 (4.9)

6 (14.6)

4 (9.8)

48 (55.8)

14 (16.3)

37 (43.0)

5 (5.8)

11 (12.8)

2 (2.3)

.04

.07

.47

<.001

.94

.01

Plasma sodium normalisation (%)

84 (57.1)

12 (60.0)

24 (58.5)

48 (55.8)

.92

Death during hospitalisation (%)

36 (24.5)

2 (10.0)

13 (31.7)

21 (24.4)

.17

Death during follow-up (%)

74 (50.3)

8 (40.0)

21 (51.2)

45 (52.3)

.64

  1. Group A: plasma sodium <110 mmol/l; group B: plasma sodium 110–115 mmol/l; group C: plasma sodium 116–120 mmol/l. CSWS Cerebral Salt Wasting Syndrome, SIADH Syndrome of Inappropriate Anti-Diuretic Hormone secretion. abetween group A, B and C